Clinical trial
A Phase 2 Double-blind, Randomized Study to Evaluate the Antiviral Activity, Safety, and Efficacy of Orally Administered PBI-0451(Pomotrelvir) Compared With Placebo in Nonhospitalized Symptomatic Adults With COVID-19
NCT05543707 is registered in ClinicalTrials.gov with Pardes Biosciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Double-blind, Randomized Study to Evaluate the Antiviral Activity, Safety, and Efficacy of Orally Administered PBI-0451(Pomotrelvir) Compared With Placebo in Nonhospitalized Symptomatic Adults With COVID-19
- Lead sponsor
- Pardes Biosciences, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- September 21, 2022
- Completion date
- April 14, 2023
- Enrollment
- 242 (actual)
- Sites
- 54
Conditions
As the registry lists them; a condition with its own page is linked.